The decisions made at the Greater Manchester Medicines Management Group (GMMMG) December 2024 meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in December 2024 and NICE Technology appraisals published in August 2024.
Updates to formulary and RAG list
- Budesonide 9mg prolonged-release tablets (Cortiment) – green (following specialist advice)
- Risankizumab for ulcerative colitis – red
- Abaloparatide for osteoporosis – red
- Linzagolix for uterine fibroids – green (specialist advice)
- Relugolix for prostate cancer – amber; added as red (pending shared care protocol)
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.